The pharmaceutical industry stands at a crossroads where regulatory expectations continue to evolve, patient safety remains paramount, and competitive pressures demand operational excellence. In this complex landscape, organizations …
The Raw Material Risks You Can’t Afford to Ignore: Ignoring raw material risks like unpredictable supply chains, political upheaval, or dwindling resource can seriously disrupt production, drive up costs, and weaken a company’s ability to bounce back.
Pharmacovigilance, the science, and activities related to detecting, assessing, understanding, and preventing adverse effects or other drug-related problems, is critical in patient safety.
Health Canada has released a new Draft Good Manufacturing Practices (GMP) Guide for Natural Health Products (NHPs), marking a significant update in the regulation of supplements, herbal remedies, vitamins, and other natural health products in Canada. If you’re a manufacturer, distributor, or consumer of NHPs, this draft guide is worth paying attention to—it could shape
The biopharmaceutical industry operates within a complex web of regulatory requirements, demanding meticulous attention to quality and compliance at every stage of a project. From early-stage research to commercial manufacturing, deviations can have significant consequences, impacting patient safety, product efficacy, and the company’s reputation. Optimizing quality and compliance is not merely about ticking boxes; it’s a strategic imperative that drives efficiency, reduces risks, and fosters innovation.